Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

By R. Furie, M. Khamashta, J. Merrill, V. Werth, K. Kalunian, P. Brohawn, G. Illei, J. Drappa, Liangwei Wang, S. Yoo. Arthritis & Rheumatology, 2017

776 citations recorded by the source corpus.

To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate‐to‐severe systemic lupus erythematosus (SLE).

Subfields: Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/25963bc4eb47b3cda3e6e9e76278e45afe458c94

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Fava
2. M. Petri

Citations in the corpus

• Systemic lupus erythematosus: Diagnosis and clinical management. (2019, background): “In a phase 2b trial, 305 lupus patients were randomized to receive placebo or one of two dosages of anifrolumab [235].”